jRCT2071230124进行中（未招募）不适用
ONO-4059-13: A Multicenter, phase I, open-label, uncontrolled study of ONO-4059 in combination with rituximab, methotrexate, procarbazine, and vincristine (R-MPV) therapy for Untreated primary central nervous system lymphoma (PCNSL)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 20
- 主要终点
- tolerability
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients diagnosed with PCNSL
- •Patients who have not received treatment for PCNSL in the past
- •Patients with ECOG Performance Status 0-2
- •Patients expected to survive for 6 months or more
排除标准
- •1.Patients with intraocular PCNSL without brain lesions
- •2.Patients are unable to swallow oral medications
结局指标
主要结局
tolerability
To confirm the tolerability of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients
safety
To confirm the safety of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients
次要结局
- Pharmacokinetics of ONO-4059
- Efficacy of ONO-4059
研究者
相似试验
招募中
不适用
A Phase I study evaluating safety, tolerability, and immunogenicity of FPP004X (FPP004X-JP-SAR-01)jRCT2031250033FunPep Co., Ltd.93
招募中
1 期
Phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in men with biochemical recurrence of prostate cancerbiochemical recurrence after curativelyintended therapy for localized PCDRKS00031816niversitätsklinikum Tübingen38
已完成
不适用
Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics and pharmacodynamics of monoclonal antibody TB31F in healthy malaria-naïve adults in the NetherlandsmalariaNL-OMON50099Radboud Universitair Medisch Centrum25
已完成
1 期
Safety, tolerability and pharmacokinetics study of WCK 2349 (in single doses) in healthy male volunteer.CTRI/2009/091/000377Wockhardt Ltd84
进行中（未招募）
不适用
Clinical trial to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of HM95573 in solid tumorNeoplasmsKCT0001539Hanmi Pharm72